BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10845927)

  • 1. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.
    Barth S; Huhn M; Matthey B; Tawadros S; Schnell R; Schinköthe T; Diehl V; Engert A
    Blood; 2000 Jun; 95(12):3909-14. PubMed ID: 10845927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.
    Klimka A; Barth S; Matthey B; Roovers RC; Lemke H; Hansen H; Arends JW; Diehl V; Hoogenboom HR; Engert A
    Br J Cancer; 1999 Jun; 80(8):1214-22. PubMed ID: 10376974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice.
    Barth S; Huhn M; Matthey B; Schnell R; Tawadros S; Schinköthe T; Lorenzen J; Diehl V; Engert A
    Int J Cancer; 2000 Jun; 86(5):718-24. PubMed ID: 10797296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo.
    Matthey B; Borchmann P; Schnell R; Tawadros S; Lange H; Huhn M; Klimka A; Tur MK; Barth S; Engert A; Hansen HP
    Int J Cancer; 2004 Sep; 111(4):568-74. PubMed ID: 15239135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant immunotoxins for the treatment of Hodgkin's disease (Review).
    Matthey B; Engert A; Barth S
    Int J Mol Med; 2000 Nov; 6(5):509-14. PubMed ID: 11029515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
    Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
    Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines.
    Barth S; Huhn M; Wels W; Diehl V; Engert A
    Int J Mol Med; 1998 Jan; 1(1):249-56. PubMed ID: 9852227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma.
    Barth S; Matthey B; Huhn M; Diehl V; Engert A
    Cytokines Cell Mol Ther; 1999 Jun; 5(2):69-78. PubMed ID: 10515679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines.
    Tur MK; Sasse S; Stöcker M; Djabelkhir K; Huhn M; Matthey B; Gottstein C; Pfitzner T; Engert A; Barth S
    Int J Mol Med; 2001 Nov; 8(5):579-84. PubMed ID: 11605031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
    Bruell D; Bruns CJ; Yezhelyev M; Huhn M; Müller J; Ischenko I; Fischer R; Finnern R; Jauch KW; Barth S
    Int J Mol Med; 2005 Feb; 15(2):305-13. PubMed ID: 15647848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.
    Tur MK; Huhn M; Jost E; Thepen T; Brümmendorf TH; Barth S
    Int J Cancer; 2011 Sep; 129(5):1277-82. PubMed ID: 21077160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma.
    Borchmann P; Treml JF; Hansen H; Gottstein C; Schnell R; Staak O; Zhang HF; Davis T; Keler T; Diehl V; Graziano RF; Engert A
    Blood; 2003 Nov; 102(10):3737-42. PubMed ID: 12881320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma.
    Pasqualucci L; Wasik M; Teicher BA; Flenghi L; Bolognesi A; Stirpe F; Polito L; Falini B; Kadin ME
    Blood; 1995 Apr; 85(8):2139-46. PubMed ID: 7718885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
    Terenzi A; Bolognesi A; Pasqualucci L; Flenghi L; Pileri S; Stein H; Kadin M; Bigerna B; Polito L; Tazzari PL; Martelli MF; Stirpe F; Falini B
    Br J Haematol; 1996 Mar; 92(4):872-9. PubMed ID: 8616080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human interleukin-9 (rhIL-9-ETA') shows specific cytotoxicity against IL-9-receptor-expressing cell lines.
    Klimka A; Barth S; Drillich S; Wels W; van Snick J; Renauld JC; Tesch H; Bohlen H; Diehl V; Engert A
    Cytokines Mol Ther; 1996 Sep; 2(3):139-46. PubMed ID: 9384698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease.
    da Costa L; Renner C; Hartmann F; Pfreundschuh M
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S33-6. PubMed ID: 10950145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.
    Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
    J Immunother; 1999 Nov; 22(6):473-80. PubMed ID: 10570745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments.
    Nagata S; Onda M; Numata Y; Santora K; Beers R; Kreitman RJ; Pastan I
    Clin Cancer Res; 2002 Jul; 8(7):2345-55. PubMed ID: 12114439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated pseudomonas exotoxin.
    Rozemuller H; Chowdhury PS; Pastan I; Kreitman RJ
    Int J Cancer; 2001 Jun; 92(6):861-70. PubMed ID: 11351308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice.
    Engert A; Gottstein C; Bohlen H; Winkler U; Schön G; Manske O; Schnell R; Diehl V; Thorpe P
    Int J Cancer; 1995 Oct; 63(2):304-9. PubMed ID: 7591221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.